Chimerix (CMRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from JonesTrading maintained a Buy rating on the stock and has a $7.00 price target.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Soumit Roy’s rating is based on Chimerix’s strategic progress and potential upcoming catalysts. The company is anticipating an important 2025, with the FDA’s decision on their New Drug Application for dordaviprone in high-grade gliomas expected by mid-March. If granted priority review, Chimerix could see a significant cash influx and a set Prescription Drug User Fee Act (PDUFA) date by the third quarter of 2025.
Chimerix is actively preparing for commercialization and has expanded its capabilities across market access, distribution, and other commercial avenues. The company’s strategy includes a robust sales team and finalized manufacturing plans in anticipation of a potential drug roll-out. Furthermore, their ongoing Phase 3 ACTION trial may deliver pivotal data in the third quarter of 2025, contributing to a promising outlook for the stock.
Roy covers the Healthcare sector, focusing on stocks such as Chimerix, Elicio Therapeutics, and aTyr Pharma. According to TipRanks, Roy has an average return of -23.8% and a 18.46% success rate on recommended stocks.